Spotlight on a selection of top Late-breaking Trials presented at PCR London Valves 2024

View a snapshot of the results of these 3 trials presented in London: TRISCEND II, COMPARE-TAVI cohort B and the 30-day Outcomes of the TF J-VALVE for Chronic AR

Table of content

TRISCEND Trial
Compare TAVI IItrial: cohort B
30D Outcomes of the TF J-VALVE for Chronic AR

TRISCEND II Trial

A study to ascertain whether Transcatheter Valve Replacement improves outcomes in symptomatic severe tricuspid regurgitation

Outcome: TTVR was superior to medical therapy for the primary composite outcome in adults with symptomatic severe TR

Compare TAVI trial: cohort B

A benchmark of the performance and safety of new THVs against best-in-practice THVs

Outcome: Myval THV series was non-inferior to Sapien THV for composite endpoint at 1-y

30D Outcomes of the TF J-VALVE for Chronic AR

An assessment of safety and effectiveness of the new J-valve THV system for severe aortic regurgitation (AR) in patients at high or prohibitive surgical risk - 127 cases.

Outcome: Transfemoral J-valve THV showed early safety and effectiveness in severe AR.